TSHATaysha Gene Therapies, Inc.
Price
+59%1YEnd-of-day closes, not the intraday tick.
A mixed picture: the questions disagree
Nothing alarming, growth fading, the market undecided.
We are a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. Our lead clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. With a singular focus on developing transformative medicines, we aim to address severe unmet medical needs and dramatically improve the lives of patients and their caregivers.
In the company’s own words · 10-K filed Mar 19, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
Taysha Gene Therapies, Inc. (TSHA) reported revenue of $0 in Q2 2026 (quarter ended Jun 30, 2026), down 100% from the same quarter a year earlier. That came with net loss of $47M. For the full year FY2025, revenue was $9.8M (+17% year on year) and net income −$109M. The next results filing is expected around Nov 3, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 11, 2026Taysha Gene Therapies Reports Second Quarter 2026 Financial Results and Provides Corporate Update.Earnings release · press release
- Jun 25, 2026On June 24, 2026, Taysha Gene Therapies, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC and Goldman Sachs & Co. LLC, as representatives of the several underwriters set forth therein (collectively, the “Underwriters”), to issue and sell 32,500,001 shares of …Material agreement entered · Form 8-K
- Jun 22, 2026Clinical and Regulatory Update Presentation On June 22, 2026, the Company also made available a presentation to be used to discuss the clinical and regulatory updates on TSHA-102.Regulation FD disclosure · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.